



## OPEN ACCESS

EDITED AND REVIEWED BY  
Valentina De Falco,  
National Research Council (CNR), Italy

## \*CORRESPONDENCE

Baorui Liu  
✉ baoruiliu@nju.edu.cn  
Tao Wu  
✉ twu@bjmu.edu.cn  
Zhendong Hu  
✉ hu\_zhendong@aliyun.com

<sup>†</sup>These authors share first authorship

RECEIVED 14 April 2025  
ACCEPTED 06 May 2025  
PUBLISHED 16 May 2025

## CITATION

Ren W, Zhang H, Li Y, Sun W, Peng H, Guo H, Hou T, Wang M, Hu Z, Wu T and Liu B (2025) Corrigendum: Efficacy and safety of PD-1/PD-L1 inhibitors as first-line treatment for esophageal squamous cell carcinoma: a systematic review and meta-analysis. *Front. Immunol.* 16:1611591. doi: 10.3389/fimmu.2025.1611591

## COPYRIGHT

© 2025 Ren, Zhang, Li, Sun, Peng, Guo, Hou, Wang, Hu, Wu and Liu. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Corrigendum: Efficacy and safety of PD-1/PD-L1 inhibitors as first-line treatment for esophageal squamous cell carcinoma: a systematic review and meta-analysis

Wei Ren<sup>1†</sup>, Hanyu Zhang<sup>2†</sup>, Yixin Li<sup>2†</sup>, Wu Sun<sup>1†</sup>, Hexiang Peng<sup>2</sup>, Huangda Guo<sup>2</sup>, Tianjiao Hou<sup>2</sup>, Mengying Wang<sup>3,4</sup>, Zhendong Hu<sup>5\*</sup>, Tao Wu<sup>2,3\*</sup> and Baorui Liu<sup>1\*</sup>

<sup>1</sup>The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, China, <sup>2</sup>Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China, <sup>3</sup>Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of Education, Beijing, China, <sup>4</sup>Department of Nutrition and Food Hygiene, School of Public Health, Peking University, Beijing, China, <sup>5</sup>Department of Esophageal Surgery, Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China

## KEYWORDS

PD-1/PD-L1 inhibitor, esophageal squamous cell carcinoma, meta-analysis, immunotherapy, combined positive score

## A Corrigendum on

**Efficacy and safety of PD-1/PD-L1 inhibitors as first-line treatment for esophageal squamous cell carcinoma: a systematic review and meta-analysis**

by Ren W, Zhang H, Li Y, Sun W, Peng H, Guo H, Hou T, Wang M, Hu Z, Wu T and Liu B (2025). *Front. Immunol.* 16:1563300. doi: 10.3389/fimmu.2025.1563300

In the published article, there was an error in **Figure 3** and **Figure 4** as published. The trend line visualization in the original **Figure 3** was incomplete. The hierarchical annotation in the original **Figure 4** erroneously uses the symbol “=” instead of “≥” for stratification labels. The corrected **Figure 3** and **Figure 4** and its caption

“Figure 3 Forest plot of subgroup analysis comparing the overall survival HR in patients who received PD-1/PD-L1 inhibitor-based therapy versus chemotherapy based on different PDL1 expression levels of CPS (A) and TPS (B).”

“Figure 4 Forest plot of subgroup analysis comparing the progression-free survival HR in patients who received PD-1/PD-L1 inhibitor-based therapy versus chemotherapy based on different PDL1 expression levels of CPS (A) and TPS (B).” appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.




FIGURE 3 Forest plot of subgroup analysis comparing the overall survival HR in patients who received PD-1/PD-L1 inhibitor-based therapy versus chemotherapy based on different PDL1 expression levels of CPS (A) and TPS (B).

